Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

PDS Biotechnology Corporation - Common Stock (NQ:PDSB)

0.8636 +0.2783 (+47.55%)
Streaming Delayed Price Updated: 12:09 PM EDT, Sep 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about PDS Biotechnology Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
PullBack Stocks PDSB, PRSO, IGC, RETO: Who Breaks First?
Via AB Newswire
Topics Artificial Intelligence
News headline image
Small-Cap Stocks VEEA, ANY, MEDS, MYSZ Watch Now
Via AB Newswire
Topics Artificial Intelligence
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Tuesday's session: most active stocks ↗
Via Chartmill
PDS Biotech (NASDAQ:PDSB) Posts Narrower Q1 Loss, Pre-Market Rises Over 5% ↗
Via Chartmill
News headline image
Earnings Scheduled For November 13, 2025 ↗
 
Via Benzinga
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
Keep an eye on the top gainers and losers in Tuesday's session. ↗
Via Chartmill
What's going on in today's after hours session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
Top movers analysis one hour before the close of the markets on 2026-09-08: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
Defense Tech Stocks MOBX, PRSO Advance Across Fighter Jets, Military Robotics
Via AB Newswire
Topics Artificial Intelligence Supply Chain
Curious about the most active stocks on Tuesday? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's regular session. The market value of their outstanding shares is at $162.5 million. PDS Biotechnology... 
Via Benzinga
Top movers analysis in the middle of the day on 2026-09-08: top gainers and losers in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks have an unusual volume in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
News headline image
PDSB Q4 2025 Earnings Call Transcript ↗
PDSB Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
PDSB Q1 2026 Earnings Transcript ↗
PDSB Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
PDS Biotechnology Q1 Earnings Call Highlights ↗
PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck cancer trial that management said could shorten development timelines and... 
Via MarketBeat
Topics Earnings
What's going on in today's after hours session ↗
Via Chartmill
News headline image
PDS BIOTECHNOLOGY CORP (NASDAQ:PDSB) Reports Q3 2025 Earnings Beat, Stock Surges 64% in Pre-Market ↗
PDS Biotech (PDSB) Q3 2025 earnings beat EPS estimates, sparking a major pre-market surge. The clinical-stage biotech also announced key progress for its lead cancer therapy. 
Via Chartmill
Topics Earnings
News headline image
A Look Ahead: PDS Biotechnology's Earnings Forecast ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
PDS Biotechnology Stock Logs Best Session In 2 Months After FDA Fast-Track Push For Cancer Drug — Retail Bets On Early Approval ↗
The company requested a meeting with the FDA to discuss an accelerated approval pathway for its lead cancer drug, PDS0101, following strong final data from its VERSATILE-002 trial. 
Via Stocktwits
News headline image
Align Technology Stock Surges After-Hours On Teen Demand — Retail Sees Rally Ahead Into 2026 ↗
Q3 revenue of $995.7 million beat Align’s own forecast range of $965 million to $985 million, fueled by strong growth in clear aligners for teens and kids. 
Via Stocktwits
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.